Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Revenue Drivers
GILD logo

Gilead's Net Income Surges 138% to $3.1B Amid HIV Strength and Patent Wins

GILD10-QFiling Date: 11/8/2025
Gilead Sciences, Inc.
Description

What this story covers

Gilead Sciences' Q3 2025 10-Q reveals $7.8B revenues up 3%, driven by 4% HIV growth to $5.3B and royalty boosts, with net income at $3.1B. Strategic wins include Biktarvy patent extensions to 2036 and Yeztugo approvals. Costs controlled, liquidity solid at $9.3B, but risks from pricing reforms and trials loom.

Story snapshot

CompanyGilead Sciences, Inc.
TickerGILD
VariantStandard detailed
Duration13:26
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000882095-25-000047

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in